On the other hand, the indication for allo‐HCT in CR1 in AML patients with NPM1 mutation and FLT3‐ITD low allelic ratio, who also belong to the ELN favorable risk group remains controversial.9, 24. This evidence concerns the gene FLT3 and acute myeloid leukemia.